This cross-health project contains four research pillars that have an urgent common need for high throughput automatization of cell-based assays.

Pillar 1 is related to mRNA-based vaccines and -therapies and mainly involves contract research (R&D) resulting from UGent fundamental research.

Pillar 2 focuses on a novel family of polymers (UGent patent pending) with excellent mRNA delivery capacities, whose valorization tract has been initiated in a recent StartTT project.

Pillar 3 involves research related to the immunology of gastrointestinal therapies/diseases and comprises contract and basic research activities.

Pillar 4 will focus on an innovative topic for AUGent, i.e. veterinary gut and tumor organoids. The latter research line is envisaged to generate valorization related to veterinary and potentially also human (cancer) therapies.